Biote Reaffirms 2024 Financial Guidance, With Acceleration In H2 Growth; Sees Revenue Of $200M-$204M, Est $203.167M; Adjusted EBITDA Of $60M-$63M
Biote Reaffirms 2024 Financial Guidance, With Acceleration In H2 Growth; Sees Revenue Of $200M-$204M, Est $203.167M; Adjusted EBITDA Of $60M-$63M
Biote重申了2024年的財務指導，下半年的增長加速；預計收入爲2億至2.04億美元，約合2.03167億美元；調整後的息稅折舊攤銷前利潤爲6000萬至6300萬美元
Previously, Biote projected fiscal 2024 revenue of greater than $200 million and Adjusted EBITDA of greater than $60 million. First half 2024 consolidated year-on-year revenue growth is expected to be in the low-single digits, with significant improvement expected in the second half of 2024. Total revenue growth in the first half of 2024 is expected to be impacted by the transition in the nutraceutical distribution channel and timing of seasonal promotions.
此前，Biote預計2024財年收入將超過2億美元，調整後的息稅折舊攤銷前利潤將超過6000萬美元。2024年上半年的合併收入同比增長預計將處於較低的個位數，預計2024年下半年將出現顯著改善。預計2024年上半年的總收入增長將受到營養品分銷渠道過渡和季節性促銷時機的影響。